UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pulmonary arterial hypertension. New therapeutic principles improve treatment of a rare condition

Läkartidningen, 2009-08, Vol.106 (34), p.2057-2061

Ekmehag, Björn

2009

Volltextzugriff (PDF)

Pulmonell arteriell hypertension. Nya behandlingsprinciper ger förbättrad behandling vid ett ovanligt tillstånd

Läkartidningen, 2009, Vol.106 (34), p.2057

Ekmehag, Björn

2009

Volltextzugriff (PDF)

Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension

American journal of health-system pharmacy, 2021-12, Vol.78 (23), p.2110-2115

2021

Volltextzugriff (PDF)

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

The New England journal of medicine, 2021-01, Vol.384 (4), p.325-334

2021

Volltextzugriff (PDF)

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

The lancet respiratory medicine, 2021-11, Vol.9 (11), p.1266-1274

2021

Volltextzugriff (PDF)

Prostaglandin I2 Signaling and Inhibition of Group 2 Innate Lymphoid Cell Responses

American journal of respiratory and critical care medicine, 2016-01, Vol.193 (1), p.31-42

2016

Volltextzugriff (PDF)

Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial

American journal of respiratory and critical care medicine, 2022-01, Vol.205 (2), p.198-207

2022

Volltextzugriff (PDF)

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial

The lancet respiratory medicine, 2019-03, Vol.7 (3), p.239-248

2019

Volltextzugriff (PDF)

Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial

Circulation (New York, N.Y.), 2013-02, Vol.127 (5), p.624-633

2013

Volltextzugriff (PDF)

Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): A Randomized Controlled Trial

Chest, 2012-12, Vol.142 (6), p.1383-1390

2012

Volltextzugriff (PDF)

Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn

Pharmacological reviews, 2012-07, Vol.64 (3), p.540-582

2012

Volltextzugriff (PDF)

Reply to Jin et al .: Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That's the Question

American journal of respiratory and critical care medicine, 2022-05, Vol.205 (10), p.1251-1252

Nathan, Steven D

2022

Volltextzugriff (PDF)

Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results

The European respiratory journal, 2024-06, Vol.63 (6), p.2400172

2024

Volltextzugriff (PDF)

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial

Chest, 2013-09, Vol.144 (3), p.952-958

2013

Volltextzugriff (PDF)

The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension

The European respiratory journal, 2012-03, Vol.39 (3), p.589-596

2012

Volltextzugriff (PDF)

Sexual dimorphism in prostacyclin-mimetic responses within rat mesenteric arteries: A novel role for K V 7.1 in shaping IP receptor-mediated relaxation

British journal of pharmacology, 2022-04, Vol.179 (7), p.1338-1352

2022

Volltextzugriff (PDF)

Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension

Trends in pharmacological sciences (Regular ed.), 2017-06, Vol.38 (6), p.512-523

2017

Volltextzugriff (PDF)

Treprostinil palmitil inhalation powder leverages endogenous lung enzymes to provide sustained treprostinil

Expert opinion on drug delivery, 2024-08, Vol.21 (8), p.1297-1305

2024

Volltextzugriff (PDF)

Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling

American journal of respiratory and critical care medicine, 2020-05, Vol.201 (10), p.1263-1276

2020

Volltextzugriff (PDF)

Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases?

Chest, 2024-05, Vol.165 (5), p.e161-e161

2024

Volltextzugriff (PDF)

Treprostinil Effectiveness in Higher-Risk Pediatric Patients With Idiopathic and Heritable Pulmonary Arterial Hypertension

Canadian journal of cardiology, 2024-04, Vol.40 (4), p.613-621

2024

Volltextzugriff (PDF)

Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension: A Randomized Controlled Clinical Trial

Journal of the American College of Cardiology, 2010-05, Vol.55 (18), p.1915-1922

2010

Volltextzugriff (PDF)

Elevated neutrophil extracellular traps in systemic sclerosis-associated vasculopathy and suppression by a synthetic prostacyclin analog

Arthritis research & therapy, 2024-07, Vol.26 (1), p.139-11, Article 139

2024

Volltextzugriff (PDF)

Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That's the Question

American journal of respiratory and critical care medicine, 2022-05, Vol.205 (10), p.1250-1251

2022

Volltextzugriff (PDF)

ERJ Podcast June 2024: Inhaled treprostinil in pulmonary hypertension associated with COPD

The European respiratory journal, 2024-06, Vol.63 (6), p.24

2024

Volltextzugriff (PDF)

1 – 25 von 2.262

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.981)
Mit Volltextzugriff
(1.709)

Publikationsform

Artikel
(2.260)
magazinearticle
(2)

Sprache

10 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.650)
Life Sciences & Biomedicine
(1.610)
Epoprostenol - Analogs & Derivatives
(1.399)
Humans
(1.282)
Animals
(1.178)
Male
(1.093)
Epoprostenol - Pharmacology
(895)
Biological And Medical Sciences
(836)
Female
(711)
Medical Sciences
(605)
Rats
(558)
Epoprostenol - Therapeutic Use
(486)
Pharmacology & Pharmacy
(435)
Adult
(395)
Cardiovascular System & Cardiology
(394)
Hypertension, Pulmonary - Drug Therapy
(392)
Prostacyclin
(384)
Middle Aged
(355)
Epoprostenol - Administration & Dosage
(345)
Pharmacology. Drug Treatments
(337)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(2.261)
Ingenta
(1.078)
EZB Electronic Journals Library
(945)
Journals@Ovid Ovid Full Text
(919)
Access via ScienceDirect (Elsevier)
(587)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(530)
Publisher website
(462)
IngentaConnect Journals
(333)
Wiley Online Library
(274)
Wiley Online Library
(225)
Springer Journals
(159)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(102)
Oxford Journals
(74)
Taylor & Francis Journals
(61)
Oxford Journals 2020 Medicine
(54)
Taylor & Francis
(49)
Thieme - Connect here FIRST to enable access
(48)
Taylor & Francis Online
(47)
SAGE Journals
(42)
BMJ
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Pulmonary arterial hypertension. New therapeutic principles improve treatment of a rare condition

Pulmonell arteriell hypertension. Nya behandlingsprinciper ger förbättrad behandling vid ett ovanligt tillstånd

Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

Prostaglandin I2 Signaling and Inhibition of Group 2 Innate Lymphoid Cell Responses

Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial

Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial

Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): A Randomized Controlled Trial

Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn

Reply to Jin et al .: Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That's the Question

Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial

The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension

Sexual dimorphism in prostacyclin-mimetic responses within rat mesenteric arteries: A novel role for K V 7.1 in shaping IP receptor-mediated relaxation

Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension

Treprostinil palmitil inhalation powder leverages endogenous lung enzymes to provide sustained treprostinil

Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling

Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases?

Treprostinil Effectiveness in Higher-Risk Pediatric Patients With Idiopathic and Heritable Pulmonary Arterial Hypertension

Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension: A Randomized Controlled Clinical Trial

Elevated neutrophil extracellular traps in systemic sclerosis-associated vasculopathy and suppression by a synthetic prostacyclin analog

Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That's the Question

ERJ Podcast June 2024: Inhaled treprostinil in pulmonary hypertension associated with COPD

Suchergebnisse filtern